Anti-DHX9 and Anti-SCO1 antibodies in research on the impact of histone density on cancer biology
Article: "Histone density-associated molecular signatures"
The histone landscape in humans is complex: while there is only one histone H4 protein, diverse variants exist for H2A, H2B, and H3.
In addition, aberrant histone levels have been reported for several cancer cell lines.
Our Triple A Polyclonals anti-DHX9 (HPA028050) and anti-SCO1 (HPA021579) were used in western blot in a study aiming to investigate the impact of histone density on cancer biology.
By using the Cancer Cell Line Encyclopedia (CCLE) project (which has characterized more than 1300 human cancer cell lines), the authors explored proteome, transcriptome, drug resistance, and epigenetic modification patterns associated with histone density across cancer cell lines, revealing links between histone density, mitochondrial proteome composition, histone hyper-acetylation, and altered cancer drug sensitivities.
Find out more about our Triple A Polyclonals anti-DHX9 (HPA028050) and anti-SCO1 (HPA021579).